Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | TETi76 |
| Synonyms | |
| Therapy Description |
TETi76, is an inhibitor of TET-dioxygeases, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 33681816). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| TETi76 | TETi76, is an inhibitor of TET-dioxygeases, potentially resulting in decreased tumor cell proliferation and reduced tumor growth (PMID: 33681816). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH2 R140Q | leukemia | sensitive | TETi76 | Preclinical - Cell culture | Actionable | In a preclinical study, TETi76 treatment decreased viability of a leukemia cell line expressing IDH2 R140Q in culture (PMID: 33681816). | 33681816 |
| TET2 loss | leukemia | sensitive | TETi76 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, TETi76 treatment reduced viability and colony formation of a TET2-null leukemia cell line in culture, decreased viability of bone marrow derived mononuclear cells from TET2-null mouse model, and reduced tumor burden in a TET2-null subcutaneous xenograft model (PMID: 33681816). | 33681816 |
| IDH1 R132C | leukemia | sensitive | TETi76 | Preclinical - Cell culture | Actionable | In a preclinical study, TETi76 treatment decreased viability of a leukemia cell line expressing IDH1 R132C in culture (PMID: 33681816). | 33681816 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|